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R231material proteins. Ultimately, a full
understanding of the relationship
between spindle pole bodies and
other yeast MTOCs and the animal
centrosome will require the study of
fungi that have retained cilia and
thus centrioles [10], species which
have so far not attracted any recent
attention.
One notable similarity between
rMTOCs and centrosomes is that both
link the cell nucleus to the microtubule
cytoskeleton. Remarkably, the same
players appear in both contexts: thus,
SUN domain proteins together with
their KASH domain partners (Sad1 and
Kms1 in S. pombe) span the nuclear
envelope and function in meiotic
chromosome movements and nuclear
migration in species as diverse as
yeast, Dictyostelium, C. elegans,
Drosophila and vertebrates [11,12].
The microtubule minus end-directed
motor cytoplasmic dynein and its
associated proteins, including LIS1 and
NudE (of which Hrs1/Mcp6 is the
putative S. pombe ortholog), are other
conserved features [13]. While SUN
domain proteins face the nucleoplasm
and provide a link to chromosomes,
KASH domain proteins are exposed
to the cytoplasm and connect to
various cytoskeletal features, including
the centrosome. Finally, cytoplasmic
dynein provides the force for
centrosome and/or nuclear movement.
Disrupting any one of these
components is sufficient to disconnect
centrosomes from the nucleus,
although the centrosome retains
microtubule organizing activity
(e.g., [14]). Whether this is also the
case for the rMTOC remains to be
determined.With progression through meiosis
requiring the timely assembly and
disassembly of various microtubule
structures (Figure 1), there is only
a narrow window within which
rMTOC-mediated formation of a radial
microtubule array is needed. This
suggests that formation of the
rMTOC is tightly regulated. Indeed,
Hrs1/Mcp6, the key component of
the rMTOC, is specifically expressed
during meiotic prophase and is subject
to strict downregulation at
the transition from meiotic prophase to
metaphase of the first meiotic division.
Both phosphorylation and degradation
of Hrs1/Mcp6 contribute to rMTOC
inactivation at the end of meiotic
prophase to facilitate reorganization of
microtubules into a bipolar spindle [4].
Ectopic expression of Hrs1/Mcp6
interferes with bipolar spindle
formation, highlighting the importance
of controlling Hrs1/Mcp6 activity [4].
In the future, it will be important to
elucidate more details about the
regulation of Hrs1/Mcp6, namely,
the identity of the kinase that
phosphorylates Hrs1/Mcp6, when this
phosphorylation occurs, and how it
affects Hrs1/Mcp6 function.References
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DOI: 10.1016/j.cub.2012.02.036Neuroimaging: A Scanner, ColourfullyTwo recent studies report changes in human brain responses after exposure
to psilocybin, the active ingredient of hallucinogenic mushrooms. Psilocybin
increased sensory cortex responses during emotional recollection, but
decreased resting-state blood flow in prefrontal cortex, with potential
implications for treating depression.Jonathan P. Roiser1,*
and Geraint Rees1,2
The psychological effects of
hallucinogenic, or ‘magic’ mushrooms
were first documented in the medicalliterature in 1799 [1]: a forty year-old
father of four, JS, collected wild
mushrooms in London’s Green Park
and cooked them as a stew for
breakfast for himself and his four young
children. The apothecary EverardBrande described what happened
then: ‘‘Edward, one of the children
(eight years old), who had eaten a large
proportion of the mushrooms, as they
thought them, was attacked with fits
of immoderate laughter, nor could the
threats of his father or mother refrain
him. To this succeeded vertigo, and
a great deal of stupor, from which he
was roused by being called or shaken,
but immediately relapsed. [.] he
sometimes pressed his hands on
different parts of his abdomen, as if in
pain, but when roused and interrogated
as to it, he answered indifferently, yes,
Figure 1. Hallucigenic Mushrooms.
Psilocybe semilanceata (the ‘liberty cap’ mushroom), the most common psychoactive
mushrooms, and the first European species confirmed to contain psilocybin. (Photo: Georg
Mu¨ller; http://www.pilzepilze.de)
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R232or no, as he did to every other question,
evidently without any relation to what
was asked. About the same time the
father, aged forty, was attacked with
vertigo, and complained that
everything appeared black, then
wholly disappeared’’ [1]. Such
perceptual distortions, mood
fluctuation and profoundly altered
states of consciousness are now
well-documented effects of psilocybin,
found in certain species ofmushrooms,
particularly the genus Psilocybe
(Figure 1). Like lysergic acid
diethylamide (LSD), psilocybin’s
active metabolite psilocin stimulates
serotonin receptors in the brain, most
potently the 2A subtype. However,
relative to other controlled substances,
such as cocaine, amphetamine and
heroin, the neurobiological basis of
hallucinogenic drug effects is very
poorly understood. In particular,
very few laboratory studies have
investigated their effects on the human
brain. Now over 200 years after its
first description, the first two studies
[2,3] investigate the effects of
psilocybin on the human brain using
functional magnetic resonance
imaging (fMRI).
The contemporary dearth of research
into psychedelic drugs stands in
contrast with a largely forgottenliterature from an earlier, pre-PubMed
time. Before they were outlawed in
most countries in the late 1960s due
to concerns about abuse liability and
psychotic reactions, psilocybin and
LSD were not only studied, but also
used therapeutically as an adjunct
to psychotherapy [4] (for a video
on the effects of LSD: http://www.
youtube.com/watch?
v=V5d4wWGK4Ig). The trials from
that era were poorly controlled
compared to modern standards, but
encouraging preliminary results were
reported in various clinical populations,
including prisoners, alcoholics and
depressed/anxious (‘neurotic’)
patients. However, because the
administrative barriers to research
involving so-called schedule 1
substances (equivalent to class A
substances in the UK) are so high,
studies into the effects of psilocybin
in humans were largely abandoned
from the 1970s onwards.
The two recent studies [2,3] into
the effects of psilocybin on brain
responses in humans are thus notable
not just for their results, but for the
fact that they were performed at all.
Both were funded by not-for-profit
organisations, including the
Multidisciplinary Association for
Psychedelic Studies (MAPS), whichhas been lobbying for renewed
research into the potential therapeutic
effects of illegal drugs for over 20 years.
Among other projects, MAPS also
funds an ongoing study into the use
of psilocybin to alleviate anxiety in
terminally ill cancer patients [5] and
methylenedioxymethamphetamine
(MDMA, or ‘ecstasy’) in post-traumatic
stress disorder [6].
The experimental design used in
both studies was simple, scanning
a group of healthy volunteers on two
occasions separated by around two
weeks. During one of the scanning
sessions, enough intravenous
psilocybin was infused to induce clear
psychological effects, while on the
other only saline was infused. In the
first study, the volunteers were asked
to simply lie still during scanning
with their eyes closed (the so-called
‘resting state’ in brain imaging
terminology). Two types of MRI signals
were recorded: blood oxygen
level-dependent (BOLD) signals, which
are an indirect measure of neuronal
activity used in most fMRI studies, and
arterial spin labelling (ASL) signals,
which measure regional cerebral blood
flow over longer periods.
Psilocybin reduced both BOLD
signals and cerebral blood flow in
several different brain structures,
including the anterior and posterior
cingulate cortex and thalamus.
Functional coupling between the
anterior and posterior cingulate
(calculated as the scan-to-scan
correlation in BOLD signal between
the two regions over the fMRI
time-series) was also decreased
following psilocybin administration.
Moreover, across participants, the
degree of reduction in cerebral blood
flow correlated with the intensity of
psychological effects that the
participants reported following
psilocybin infusion.
Such a relationship with subjective
psychological effects is reassuring,
as it argues against an interpretation
of the changes in BOLD signal simply
in terms of blood flow, a common and
not unreasonable criticism of many
pharmacological fMRI studies. When
serotonin was first discovered, it was
identified as a potent vasoconstrictor
[7], not a neurotransmitter, and its
name even reflects this property
(‘sero’ – blood; ‘tonin’ – tone).
Moreover, its vascular effects are
mediated largely via the serotonin 2A
receptor, psilocybin’s target.
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blood flow measurements following
a pharmacological challenge with
psilocybinmight simply reflect changes
in vascular tone asopposed to neuronal
activity. The authors clearly anticipated
this confound, and added a control
condition, measuring BOLD signals
while the participants held their breath.
Breath holding induces hypercapnia
and vasodilatation, and allows the
assessment of vascular reactivity on
BOLD signals [8]. Importantly, breath
hold-induced BOLD responses
appeared unchanged following
psilocybin infusion, suggesting that
their results were not confounded by
changes in vascular tone.
Carhart-Harris and colleagues [2]
interpret their results in terms of
a decrease in activity in critical ‘hub’
regions of the brain, specifically, the
anterior and posterior cingulated
cortex, and a loss of coordination
between them, caused by the inhibitory
effects of serotonin 2A receptor
stimulation. This would trigger ‘‘a
state of unconstrained cognition’’.
Consistent with their findings, studies
in rats have suggested that cortical
local field potentials, which the BOLD
signal is believed to reflect, are
decreased following serotonin 2A
receptor stimulation [9]. However,




somewhat clouding the picture.
A second study from the same group
[3] focused not on brain activity in the
resting state, but studied BOLD signals
while participants were cued to recall
specific personal memories of positive
events from their life. Not only were
memories described as more vivid,
emotional and positive following
psilocybin infusion, but brain
responses were enhanced in visual and
auditory cortex during autobiographic
recollection. These findings led to
a somewhat different conclusion than
the first study, namely that psilocybin
focuses and enhances subjective and
neural responses to autobiographical
memory rather than resulting in a state
of ‘unconstrained cognition’. This stark
difference between the two sets of
experimental findings underscores the
difficulty in comparing results from
task-related fMRI, as in the second
study [3], in which the effects of an
experimental condition are compared
with a control condition, with thosefrom relatively unconstrained
resting-state fMRI.
On the basis of their results,
Carhart-Harris and colleagues [2,3]
suggest that psilocybin may have
potential efficacy in the treatment of
depression, especially when combined
with psychotherapy. This conjecture is
based mainly on their observations of
a reduction in resting-state cerebral
blood flow in the anterior cingulate
cortex, which is reliably hyperactive in
the depressed state [11]. While a recent
study [6] did report slightly lowered
depression scores 6 months after
psilocybinadministration in terminally ill
cancer patients, this study specifically
excluded individuals with a recent
major depressive episode. Therefore,
it remains tobeseenwhetherpsilocybin
might help to treat depression.
However, given the administrative
obstacles in conducting such a trial
under current regulatory frameworks,
it is unlikely that wewill witness a return
to the 1950s heyday of psychedelic
psychotherapy any time soon.References
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beyond the Spindle CheckpointWhat specific defects can cause chromosomal instability in cancer cells?
Overexpression of the mitotic checkpoint protein Mad2 triggers chromosome
missegregation but, surprisingly, Mad2 exerts this effect through a previously
unknown effect on microtubule dynamics.Edward R. Ballister1
and Michael A. Lampson1,2,*
In order to faithfully segregate
their chromosomes at each division,
cells must ensure that each pair of
sister chromatids is correctly attached
to spindle microtubules from oppositepoles before anaphase onset. Two
complementary systems collaborate
for this purpose: regulation of
kinetochore-microtubule dynamics
and the mitotic checkpoint.
Kinetochore-microtubule dynamics
are regulated to selectively
destabilize incorrect attachments,
